Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

208 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dermatological adverse events with taxane chemotherapy.
Sibaud V, Lebœuf NR, Roche H, Belum VR, Gladieff L, Deslandres M, Montastruc M, Eche A, Vigarios E, Dalenc F, Lacouture ME. Sibaud V, et al. Among authors: gladieff l. Eur J Dermatol. 2016 Oct 1;26(5):427-443. doi: 10.1684/ejd.2016.2833. Eur J Dermatol. 2016. PMID: 27550571 Free PMC article. Review.
Adherence to guidelines in gynecologic cancer surgery.
Ferron G, Martinez A, Gladieff L, Mery E, David I, Delannes M, Montastruc M, Balagué G, Picaud L, Querleu D. Ferron G, et al. Among authors: gladieff l. Int J Gynecol Cancer. 2014 Nov;24(9):1675-8. doi: 10.1097/IGC.0000000000000284. Int J Gynecol Cancer. 2014. PMID: 25340292 Review.
[Nurse telephone support at home during chemotherapy].
Despiau F, Bombail M, Leches C, Montastruc M, Gladieff L, Delord JP. Despiau F, et al. Among authors: gladieff l. Rev Infirm. 2015 Aug-Sep;(213):37-9. doi: 10.1016/j.revinf.2015.06.011. Rev Infirm. 2015. PMID: 26365645 French.
PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy.
Jacot W, Dalenc F, Lopez-Crapez E, Chaltiel L, Durigova A, Gros N, Lozano N, Lacaze JL, Pouderoux S, Gladieff L, Romieu G, Roché H, Filleron T, Lamy PJ. Jacot W, et al. Among authors: gladieff l. Breast Cancer Res Treat. 2019 Oct;177(3):659-667. doi: 10.1007/s10549-019-05349-y. Epub 2019 Jul 11. Breast Cancer Res Treat. 2019. PMID: 31297647
Survival impact of histological response to neoadjuvant chemotherapy according to number of cycles in patients with advanced ovarian cancer.
Betrian S, Angeles MA, Gil Moreno A, Cabarrou B, Deslandres M, Ferron G, Mery E, Floquet A, Guyon F, Pérez-Benavente A, Spagnolo E, Rychlik A, Gladieff L, Hernández Gutiérrez A, Martinez A. Betrian S, et al. Among authors: gladieff l. Int J Gynecol Cancer. 2022 Jul 20:ijgc-2021-003313. doi: 10.1136/ijgc-2021-003313. Online ahead of print. Int J Gynecol Cancer. 2022. PMID: 35858711
Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.
Bignon L, Fricker JP, Nogues C, Mouret-Fourme E, Stoppa-Lyonnet D, Caron O, Lortholary A, Faivre L, Lasset C, Mari V, Gesta P, Gladieff L, Hamimi A, Petit T, Velten M. Bignon L, et al. Among authors: gladieff l. Breast J. 2018 May;24(3):269-277. doi: 10.1111/tbj.12887. Epub 2017 Sep 19. Breast J. 2018. PMID: 28929593 Clinical Trial.
Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure.
Schmitt A, Gladieff L, Laffont CM, Evrard A, Boyer JC, Lansiaux A, Bobin-Dubigeon C, Etienne-Grimaldi MC, Boisdron-Celle M, Mousseau M, Pinguet F, Floquet A, Billaud EM, Durdux C, Le Guellec C, Mazières J, Lafont T, Ollivier F, Concordet D, Chatelut E. Schmitt A, et al. Among authors: gladieff l. J Clin Oncol. 2010 Oct 20;28(30):4568-74. doi: 10.1200/JCO.2010.29.3597. Epub 2010 Sep 20. J Clin Oncol. 2010. PMID: 20855828
208 results